ClinicalTrials.gg
RecruitingNCT06463262CanonUpdated Oct 28, 2026

Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma

An observational study in Chordoma of Spine, Chordoma of Skull Base and Chordoma of Sacrum, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 28, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Chordoma with a site in United States — 6 open to participants now, 16 under way, none of them phase 3. Chordoma · United States.

Planned enrollment
11th of 11
40 · median 150
Started
2024
the only one that year
Observational
11 of 44
4 open now
Primary completion
2029-07
later than 10 of 14 live
Registered
40th of 44
by date
Lead sponsor
2 of 44
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Among the 44 studies in Chordoma with a site in United States, this one is the 11th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2024, is one of 11 observational ones, reaches primary completion later than 10 of the 14 other live ones, and was the 40th registered.

Chordoma

68 studies on the registry are indexed under Chordoma; 15 are open to participants now.

Browse Chordoma studies →

Open to participants now

6 of the 44 studies in Chordoma with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Chordoma studies recruiting now, 9 (75%) set no upper age limit and 1 (8%) stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chordoma with a site in United States, or all of them as a file.
02

Study summary

In this study the investigators will study the effects of neoadjuvant radiation therapy (RT), in the form of either proton therapy or stereotactic body radiation therapy (SBRT), on the Circulating tumor DNA (ctDNA), radiographic changes and radiomics, and the validity of these findings will be compared using the current gold standard- pathologic findings. The purpose of this work is to explore whether the biomarkers may be used diagnostically to better understand radiographic changes following RT. The investigators hypothesize that ctDNA levels in combination with imaging biomarkers identified through radiomics will be a sensitive and specific tool for predicting histopathologic response to RT.

03

Conditions studied

  • Chordoma of Spine
  • Chordoma of Skull Base
  • Chordoma of Sacrum

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Potential participants who are clinical patients of the PI or co-investigators may be identified during chart review in advance of a routine clinic visit or during a routine clinic visit with a provider.

Patients who are enrolled in IRB: IRB00075499 (PI: Dr. Chetan Bettagowda) may be eligible for this trial as well. Once identified as a potential study participant, the study team for this ctDNA study would have to confirm eligibility as for any potential participant.

In addition, potential participants may contact the study team directly.

Some of these potential participants may also be identified during the multidisciplinary clinic as part of the standard clinic case review process.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • proven chordoma of the skull base, spine, or sacrum (coccyx lesions are eligible).
  • Radiographic evidence of spinal sacral chordoma is required and may be obtained from computed tomography imaging and/or magnetic resonance imaging. Other studies may be used with principal investigator approval.

Note: Patients enrolled in Dr. Chetan Bettegowda's J1576 study, (IRB00075499) may be considered eligible for this trial. The J1576 study enrolls patients who have been diagnosed with Chordoma. Prior to enrollment, all patients must be consented specifically for participation in this Chordoma study (IRB00291203).

  • Treating physician must deem that proton therapy or SBRT is appropriate treatment for the chordoma.
  • Surgical resection with curative intent must be planned.
  • The patient must have a Performance Score of 40 or greater.
  • If a woman is of , a negative urine or serum pregnancy test must be demonstrated prior to treatment. Women of childbearing potential and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) for the duration of study participation and for up to 12 weeks following the study. Should a woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Prior radiation or radiosurgery to the involved level of the spine.
  • Patients with disease will be excluded.
  • Prior are excluded except for adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ, or other cancer from which the patient has been disease free for at least 1 year.
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements will be excluded.
  • Pregnant women are excluded. Women of who are unwilling or unable to use and acceptable method of to avoid pregnancy for the entire study period and up to 12 weeks after the study are excluded. Male subjects must also agree to use effective contraception for the same period as above.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Spinal, Sacral Chordoma

    Diagnostic Test: ctDNA

Interventions

  • Diagnostic testctDNA

    the effects of neoadjuvant RT, in the form of either proton therapy or SBRT, on the ctDNA

06

What researchers measure

Primary outcomes

  1. Sensitivity and specificity of combining ctDNA and radiomics

    Sensitivity and specificity of combining ctDNA and radiomic features in predicting histopathologic changes at surgery defined by patients who have \<10% necrosis, the percentage of patients who are deemed "positive" by the model based on ctDNA and radiomics

    Time frame: within one week after surgery

Secondary outcomes

  1. Percent of necrotic and active tumor cells

    Percent of necrotic and active tumor cells following neoadjuvant RT using proton therapy or SBRT according to the Johns Hopkins Solid Tumor Panel Next Generation Sequencing

    Time frame: within one week after surgery

  2. Change in plasma ctDNA levels

    Change in plasma ctDNA levels following neoadjuvant RT for spinal chordoma and correlate changes in ctDNA levels with histopathologic changes at surgery

    Time frame: within one week after surgery

  3. Correlate radiomic features with histopathologic and genomic features

    Correlate radiomic features with histopathologic and genomic features in patients receiving neoadjuvant RT for spinal and sacral chordoma

    Time frame: within one week after surgery

  4. Radiographic local recurrence

    Radiographic local recurrence defined as evidence of progressive disease on CT/MRI in the operative site when compared to post-op imaging.

    Time frame: within one week after surgery

  5. Rate of wound healing complications

    Rate of wound healing complications following neoadjuvant RT for spinal chordoma

    Time frame: within one week after surgery

  6. Health related quality of life as assessed by the European Organization for Research and Treatment of Cancer (EORTC) quality of life (QLQ-C15-PAL) questionnaire

    Health related quality of life following neoadjuvant RT for spinal chordoma measured by the European Organization for Research and Treatment of Cancer (EORTC) quality of life (QLQ-C15-PAL) questionnaire. The scoring ranges from 0-21, with 21 being the highest quality of life.

    Time frame: within one week after surgery

  7. Local progression free survival

    Local progression free survival following neoadjuvant RT for spinal chordoma

    Time frame: 3 years

  8. Overall survival

    Overall survival following neoadjuvant RT for spinal chordoma

    Time frame: 3 years

  9. Relationship between ctDNA post-op and local Progression Free Survival (PFS)

    The relationship between circulating tumor DNA post-operatively and local PFS following neoadjuvant RT for spinal chordoma

    Time frame: 3 years

  10. Relationship between ctDNA post-op and Overall Survival (OS)

    The relationship between circulating tumor DNA post-operatively and OS following neoadjuvant RT for spinal chordoma

    Time frame: 3 years

  11. Toxicity of neoadjuvant RT as assessed by CTCAE version 5

    Toxicity of neoadjuvant RT for chordoma using CTCAE version 5

    Time frame: 3 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jul 2029, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 17, 2024
StartActual
Jun 14, 2024
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2031
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: j•••@jhmi.edu · •••8335→i•••@jhmi.edu · •••8334. See the current contact
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Contact Study contact changed: j•••@jhmi.edu · •••8335→i•••@jhmi.edu · •••8334. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06463262
Collaborators
Canon Medical Systems, USA
Responsible party
Sponsor
First posted
Jun 17, 2024
Start date
Jun 14, 2024
Primary completion
Jul 2029 (estimated)
Completion
Jul 2031 (estimated)
Last update
Oct 28, 2026

Study contacts

Kristin Redmond, MD, MPH
Contact
kjanson3@jhmi.edu
4106141642
Imani Fortt
Contact
ifortt1@jhmi.edu
6673068334
Kristin Redmond, MD, MPH
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion